Screener
Veracyte VCYT Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Direct research and development expense | 4,198 | 4,141 |
| Other research and development expenses (4) | 5,460 | 1,815 |
| Allocation of facilities and IT expenses | 1,893 | 2,016 |
| Total research and development | 27,098 | 17,720 |
| Selling and marketing: | ||
| Compensation expense | 19,972 | 17,635 |
| Direct marketing expense | 1,455 | 710 |
| Other selling and marketing expenses (5) | 4,561 | 3,853 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's business segments — R&D?
- Veracyte (VCYT) reported business segments — R&D of $27.1M in Q1 2026.
- How has Veracyte's business segments — R&D changed year-over-year?
- Veracyte's business segments — R&D increased by 52.9% year-over-year, from $17.72M to $27.1M.
- What is the long-term trend for Veracyte's business segments — R&D?
- Over 3 years (2022 to 2025), Veracyte's business segments — R&D has grown at a 20.4% compound annual growth rate (CAGR), from $40.6M to $70.81M.
- What does business segments — R&D mean?
- The total investment made by the reportable segment into innovation, product development, and clinical or technical advancement. This metric is critical for evaluating the segment's long-term growth potential and competitive pipeline.
Ask your AI about Veracyte's business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude